MX2016010995A - Novedoso anticuerpo anti-presepsina. - Google Patents
Novedoso anticuerpo anti-presepsina.Info
- Publication number
- MX2016010995A MX2016010995A MX2016010995A MX2016010995A MX2016010995A MX 2016010995 A MX2016010995 A MX 2016010995A MX 2016010995 A MX2016010995 A MX 2016010995A MX 2016010995 A MX2016010995 A MX 2016010995A MX 2016010995 A MX2016010995 A MX 2016010995A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- presepsin
- novel anti
- antigen
- presepsin antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
La presente invención aborda el problema de proporcionar un nuevo anticuerpo monoclonal que tiene una excelente reactividad con presepsina y es adecuado para medir presepsina en una muestra, o un fragmento de anticuerpo de unión a un antígeno de dicho anticuerpo. Se proporciona un anticuerpo anti-presepsina que reconoce específicamente un epítopo que comprende una SEC ID NO: 1 secuencia de aminoácido, o un fragmento de anticuerpo de unión a un antígeno de dicho anticuerpo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461944674P | 2014-02-26 | 2014-02-26 | |
| PCT/JP2015/055488 WO2015129774A1 (ja) | 2014-02-26 | 2015-02-25 | 新規抗プレセプシン抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016010995A true MX2016010995A (es) | 2017-02-27 |
Family
ID=53881586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010995A MX2016010995A (es) | 2014-02-26 | 2015-02-25 | Novedoso anticuerpo anti-presepsina. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9951142B2 (es) |
| EP (2) | EP3628731B1 (es) |
| JP (4) | JP6567496B2 (es) |
| KR (1) | KR102360851B1 (es) |
| CN (1) | CN106255751B (es) |
| AU (1) | AU2015223840B2 (es) |
| BR (1) | BR112016019739B1 (es) |
| CA (1) | CA2938956C (es) |
| ES (2) | ES2880225T3 (es) |
| LT (1) | LT3628731T (es) |
| MX (1) | MX2016010995A (es) |
| NZ (1) | NZ722440A (es) |
| PH (1) | PH12016501579A1 (es) |
| PL (2) | PL3628731T3 (es) |
| RS (2) | RS59549B1 (es) |
| RU (1) | RU2710439C2 (es) |
| SI (1) | SI3628731T1 (es) |
| WO (1) | WO2015129774A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3628731T3 (pl) | 2014-02-26 | 2021-11-15 | Mochida Pharmaceutical Co., Ltd. | Nowe przeciwciało przeciwko presepsynie |
| ES2875420T3 (es) * | 2015-08-25 | 2021-11-10 | Mochida Pharm Co Ltd | Anticuerpo antipresepsina específicamente purificado |
| CN108680634B (zh) * | 2018-08-28 | 2023-09-08 | 长沙理工大学 | 一种基于谷胱甘肽修饰栅极金电极的l-胱氨酸的检测方法及传感器 |
| CN115232211A (zh) * | 2019-11-19 | 2022-10-25 | 武汉全景生物技术有限公司 | 新的抗可溶性cd14亚型抗体及其应用 |
| EP4092051A4 (en) * | 2020-06-18 | 2023-09-06 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd | SOLUBLE ANTI-SUBTYPE CD14 ANTIBODY, KIT AND CORRESPONDING USE |
| CN113555118B (zh) * | 2021-07-26 | 2023-03-31 | 内蒙古自治区人民医院 | 一种病症程度的预测方法、装置、电子设备及存储介质 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7465547B2 (en) * | 2002-11-12 | 2008-12-16 | Mochida Pharmaceutical Co., Ltd. | Methods for detecting human low molecular weight CD14 |
| US7608684B2 (en) * | 2002-11-12 | 2009-10-27 | Mochida Pharmaceuticals Co., Ltd. | Soluble CD14 antigen |
| JP2005106694A (ja) * | 2003-09-30 | 2005-04-21 | Mochida Pharmaceut Co Ltd | 敗血症早期検出及び重篤度評価 |
| JP4040666B2 (ja) * | 2004-05-11 | 2008-01-30 | 持田製薬株式会社 | 新規可溶性ｃｄ１４抗原 |
| JP4891125B2 (ja) | 2005-06-03 | 2012-03-07 | 持田製薬株式会社 | 抗ｃｄ１４抗体融合蛋白質 |
| US7429487B2 (en) | 2005-07-05 | 2008-09-30 | Epitomics, Inc. | Fusion partner for production of monoclonal rabbit antibodies |
| ES2628944T3 (es) | 2008-05-23 | 2017-08-04 | Mochida Pharmaceutical Co., Ltd. | Método para la evaluación de la función de fagocitos |
| CN102713636B (zh) * | 2010-01-29 | 2015-06-17 | 美迪恩斯生命科技株式会社 | 人sCD14-ST的分析方法 |
| US20130337476A1 (en) * | 2012-06-13 | 2013-12-19 | Min-Yi Lee | URINARY sCD14 AS A BIOMARKER FOR CORONARY ARTERY DISEASE |
| PL3628731T3 (pl) * | 2014-02-26 | 2021-11-15 | Mochida Pharmaceutical Co., Ltd. | Nowe przeciwciało przeciwko presepsynie |
| ES2875420T3 (es) | 2015-08-25 | 2021-11-10 | Mochida Pharm Co Ltd | Anticuerpo antipresepsina específicamente purificado |
-
2015
- 2015-02-25 PL PL19188513T patent/PL3628731T3/pl unknown
- 2015-02-25 EP EP19188513.6A patent/EP3628731B1/en active Active
- 2015-02-25 RS RS20191464A patent/RS59549B1/sr unknown
- 2015-02-25 JP JP2016505279A patent/JP6567496B2/ja active Active
- 2015-02-25 PL PL15755779T patent/PL3112463T3/pl unknown
- 2015-02-25 NZ NZ722440A patent/NZ722440A/en unknown
- 2015-02-25 CA CA2938956A patent/CA2938956C/en active Active
- 2015-02-25 SI SI201531652T patent/SI3628731T1/sl unknown
- 2015-02-25 AU AU2015223840A patent/AU2015223840B2/en active Active
- 2015-02-25 EP EP15755779.4A patent/EP3112463B1/en active Active
- 2015-02-25 WO PCT/JP2015/055488 patent/WO2015129774A1/ja active Application Filing
- 2015-02-25 LT LTEP19188513.6T patent/LT3628731T/lt unknown
- 2015-02-25 KR KR1020167022978A patent/KR102360851B1/ko active IP Right Grant
- 2015-02-25 MX MX2016010995A patent/MX2016010995A/es active IP Right Grant
- 2015-02-25 RU RU2016137807A patent/RU2710439C2/ru active
- 2015-02-25 ES ES19188513T patent/ES2880225T3/es active Active
- 2015-02-25 US US14/631,668 patent/US9951142B2/en active Active
- 2015-02-25 CN CN201580010130.6A patent/CN106255751B/zh active Active
- 2015-02-25 BR BR112016019739-9A patent/BR112016019739B1/pt active IP Right Grant
- 2015-02-25 RS RS20210737A patent/RS62033B1/sr unknown
- 2015-02-25 ES ES15755779T patent/ES2753400T3/es active Active
-
2016
- 2016-08-10 PH PH12016501579A patent/PH12016501579A1/en unknown
-
2018
- 2018-03-08 US US15/915,658 patent/US10676532B2/en active Active
-
2019
- 2019-07-30 JP JP2019140149A patent/JP6759429B2/ja active Active
-
2020
- 2020-05-01 US US16/864,673 patent/US11685788B2/en active Active
- 2020-09-01 JP JP2020146561A patent/JP2021003115A/ja active Pending
-
2022
- 2022-11-15 JP JP2022182243A patent/JP2023025047A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501579A1 (en) | Novel anti-presepsin antibody | |
| MX2017001401A (es) | Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas. | |
| PH12016501212A1 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| EA201892417A1 (ru) | Антитела, распознающие тау | |
| JO3792B1 (ar) | تركيبات الجسم المضاد لـ flt3 و cd3 | |
| MX2021008367A (es) | Constructos de anticuerpos para cdh19 y cd3. | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| SG10201901057UA (en) | Anti-pd-l1 antibodies | |
| PH12015501505A1 (en) | Antibodies that bind to tl1a and their uses | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| BR112017009817A2 (pt) | anticorpos anti-il-1beta e métodos de utilização | |
| EA201892412A1 (ru) | Антитела, распознающие тау | |
| AU2015287227A8 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
| MX2017005642A (es) | Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso. | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
| CU24556B1 (es) | Anticuerpos anti-basigin humanizados | |
| EA201890739A1 (ru) | Анти-s100a8 для лечения лейкемии | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
| MY197202A (en) | A liquid formulation of anti-tnf alpha antibody | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |